Problem 28 - Chemistry: Introducing Inorganic, Organic and Physical Chemistry

Question

After intravenous injection of a drug to treat hypertension (high blood pressure), the blood plasma of the patient was analysed for the remaining drug at various times after the injection. (Section 9.5 ) $$\begin{array}{lllllllll} t / \min & 50 & 100 & 150 & 200 & 250 & 300 & 400 & 500 \\ {[\mathrm{drug}] / 10^{-9} \mathrm{g} \mathrm{cm}^{-3}} & 650 & 445 & 304 & 208 & 142 & 97 & 45 & 21 \end{array}$$ (a) Is the removal of the drug in the body a first or a second order process? (b) Calculate the rate constant, \(k\), and the half life, \(t_{1 / 2}\), for the process. (c) An essential part of drug development is achieving an optimum value of \(t_{1 / 2}\) for effective operation and elimination of the drug from the bloodstream. What would be the possible problems if \(t_{1 / 2}\) were too short or too long?

Step-by-Step Solution

Answer

(a) The process is first-order. (b) \(k \approx 0.0076 \text{min}^{-1}\), \(t_{1/2} \approx 91.2 \text{min}\). (c) Short \(t_{1/2}\) may reduce effectiveness; long \(t_{1/2}\) may cause toxicity.

Step 1: Analyze First-Order Kinetics

For a first-order reaction, the concentration of the drug over time can be described by the equation \([\ln[A](t) = -kt + \ln[A]_0]\). Check if the plot of \(\ln[\text{drug}]\) versus time \(t\) is a straight line.

Step 2: Calculate ln(concentration)

Convert the given drug concentrations to their natural logarithms: - \(\ln(650) \approx 6.476\)- \(\ln(445) \approx 6.097\)- \(\ln(304) \approx 5.716\)- \(\ln(208) \approx 5.338\)- \(\ln(142) \approx 4.955\)- \(\ln(97) \approx 4.574\)- \(\ln(45) \approx 3.807\)- \(\ln(21) \approx 3.045\)

Step 3: Check the order with linearity

Plot \(\ln[\text{drug}]\) against time \(t\). If the plot is a straight line, the process is first-order. For visual reference, the natural logs calculated earlier show decreasing linearity, consistent with first-order kinetics.

Step 4: Determine the Rate Constant \(k\)

Calculate the slope of the line \(-k\) from the first-order plot or equation. Use two points from the dataset; for example:\[-k = \frac{(3.045 - 6.476)}{(500 - 50)} = \frac{-3.431}{450}\]- Solving gives \(k \approx 0.0076 \, \text{min}^{-1}\).

Step 5: Calculating Half-Life \(t_{1/2}\)

For a first-order reaction, the half-life \(t_{1/2}\) is given by:\[t_{1/2} = \frac{0.693}{k}\]- Substitute \(k = 0.0076\)- \(t_{1/2} \approx \frac{0.693}{0.0076} \approx 91.2\, \text{minutes}\).

Step 6: Discuss Impact of Half-Life Values

A too short \(t_{1/2}\) implies rapid elimination which may reduce therapeutic effectiveness as the drug concentration might fall below the therapeutic level too quickly. On the other hand, a too long \(t_{1/2}\) could lead to drug accumulation, potentially causing toxicity.

Key Concepts

First-Order Kinetics

First-order kinetics describe a situation where the rate of drug elimination is proportional to the concentration of the drug present. This means that the higher the concentration of the drug, the faster it is eliminated from the body. Such processes are mathematically represented using the equation \[\ln[A](t) = -kt + \ln[A]_0\] where \([A]_0\) is the initial concentration, and \(k\) is the rate constant.
To determine if a process follows first-order kinetics, a logarithmic plot of concentration versus time should yield a straight line. In our given exercise, this was confirmed when the natural logarithm of drug concentration plotted against time showed linearity, confirming that the drug follows first-order kinetics at the given times.

Rate Constant Calculation

The rate constant, \(k\), is a crucial parameter in understanding the kinetics of a drug in the body. It is determined from the slope of the line in a first-order kinetic plot. When you see a straight line in a \(\ln[\text{drug}]\) versus time plot, the slope will be \(-k\).
To calculate \(k\), we select two points from the linear plot. Using the data provided in the solution, the slope was calculated as follows:
\[-k = \frac{(3.045 - 6.476)}{(500 - 50)}\]
This gives a rate constant \(k\) of approximately 0.0076 min^{-1}. This value is vital as it helps predict how quickly a drug is eliminated from the system.

Half-Life Determination

The half-life of a drug, denoted \(t_{1/2}\), is the time it takes for half of the drug to be eliminated from the bloodstream. In first-order kinetics, it is always constant and can be derived from the rate constant \(k\).
For first-order reactions, the half-life formula is:
\[t_{1/2} = \frac{0.693}{k}\]
Substituting in the calculated \(k = 0.0076\), the half-life \(t_{1/2}\) comes out to be about 91.2 minutes.
Understanding the half-life is crucial as it informs how frequently a drug needs to be administered to maintain therapeutic levels.

Drug Development

Drug development is an extensive process that ensures a drug is both effective and safe for patients. A critical aspect of this process is optimizing the half-life of the drug for its intended use. A perfectly tuned half-life ensures that a drug remains in the therapeutic range for an optimal duration, neither too short nor too long.
Considerations in drug development include:

• Fine-tuning dosage forms for desired release and absorption rates.
• Adjusting half-life to avoid frequent dosage, enhancing patient compliance.
• Ensuring stability and minimizing potential side effects.

These factors collectively assist in achieving optimal therapeutic outcomes and minimal adverse effects.

Therapeutic Efficacy

Therapeutic efficacy refers to the ability of a drug to produce the desired effect at the target site of action. It plays a pivotal role in deciding if a drug will be successful in clinical use. The half-life of a drug directly impacts its therapeutic efficacy.
Key points regarding therapeutic efficacy include:

• A too short half-life can lead to suboptimal drug levels, where the therapeutic concentration is not maintained.
• A too long half-life risks drug accumulation, which can increase the potential for adverse effects.
• Efficacy depends on maintaining drug concentration within the therapeutic window over time.

Therefore, ensuring the half-life is aligned with clinical needs is essential to achieve safe and effective treatment outcomes.